Gonadotropin-releasing hormone antagonists (GnRH-ants) have been used in assisted reproductive technology (ART) since the 1980s.[1] They have been widely used in in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) cycles because of their advantages of short duration of stimulation, little amount of gonadotropin (Gn), retention of pituitary reactivity, and low incidence of ovarian hyperstimulation syndrome (OHSS).[2]. The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.